Investors might want to bet on Pacific Biosciences of California (PACB), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend ...

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare ...

Investors in Harmony Biosciences Holdings Inc. HRMY need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 17, 2026 $05.00 Call had some of the ...

Ratings for Arcus Biosciences (NYSE:RCUS) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...

It is being acquired for quite a meaty premium. The buyer is a top name in the global pharmaceuticals space. The purchasing party is global pharmaceutical company Novartis, which on Sunday divulged ...

Gilead HPI licensing adds $35M now + $330M milestones; Phase 2 starts by 2026; strong cash runway. Click for this ASMB update ...

Neurocrine Biosciences has rebounded 60% since April 2025, driven by robust Ingrezza sales and Crenessity's uncontested launch. Read why NBIX stock is a hold.

Regencell Bioscience's investor website explains that it is an early-stage bioscience company working on TCM. It lists indications such as neurocognitive disorders and infectious diseases as areas of ...

According to its SEC filing dated February 17, 2026, Rock Springs Capital Management LP reduced its stake in Cogent Biosciences by 159,278 shares during the fourth quarter. The estimated transaction ...

Regencell Bioscience (NASDAQ: RGC) is an early-stage bioscience company. That alone should be enough to keep most investors on the sidelines, given the risks involved if the medicines the company is ...